Skip to main content

Table 5 Summary of multivariate analysis in all patients without neoadjuvant chemotherapy showing the odds ratio (95% confidence interval) of variables significantly associated with PD-L1 scoring methods and sTIL level

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

FactorTCTCICICsTIL level
Age
 ≥ 50 vs. < 50 years   0.50 (0.27, 0.92)a
Race/ethnicity
 White+Latino vs. Black 0.32 (0.14, 0.74)b0.21 (0.09, 0.53)c 
 Others vs. Black NSNS 
Histologic grade
 3 vs. 1 + 23.31 (1.38,7.93)b  4.69 (2.57, 8.57)c
sTIL level
 ≥ 10% vs. < 10%3.48 (1.50, 8.11)b12.44 (6.59, 23.49)c23.12 (10.60, 50.42)c 
Receptor group
 ER/PR pos vs. TNBC   0.20 (0.10, 0.43)c
 HER2 vs. TNBC   NS
  1. NS not significant
  2. aP value < 0.05–0.01
  3. bP value < 0.01–0.001
  4. cP value < 0.001